Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.

Autor: Zinsz A; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Ahrari S; Université de Lorraine, IADI, INSERM U1254, F-54000, Nancy, France., Becker J; Department of Neuro-Oncology, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Mortada A; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Roch V; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Doriat L; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Santi M; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Blonski M; Department of Neuro-Oncology, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Taillandier L; Department of Neuro-Oncology, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Zaragori T; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France., Verger A; Department of Nuclear Medicine and Nancyclotep Imaging Platform, Université de Lorraine, CHRU Nancy, 54000, Nancy, France. a.verger@chru-nancy.fr.; Université de Lorraine, IADI, INSERM U1254, F-54000, Nancy, France. a.verger@chru-nancy.fr.; Nuclear Medicine Department, CHRU Nancy, Rue du Morvan, 54500, Vandoeuvre Les Nancy, France. a.verger@chru-nancy.fr.
Jazyk: angličtina
Zdroj: Journal of neuro-oncology [J Neurooncol] 2024 Sep; Vol. 169 (2), pp. 241-245. Date of Electronic Publication: 2024 Jun 06.
DOI: 10.1007/s11060-024-04722-2
Abstrakt: Purpose: This study aimed to evaluate the prognostic performance of amino-acid PET in high-grade gliomas (HGG) patients at the time of temozolomide (TMZ) treatment discontinuation, after the Stupp protocol.
Methods: The analysis included consecutive HGG patients with dynamic [18F]FDOPA PET imaging within 3 months of the end of TMZ therapy, post-Stupp protocol. Static and dynamic PET parameters, responses to RANO criteria for MRI and clinical and histo-molecular factors were correlated to progression-free (PFS).
Results: Thirty-two patients (59.4 [54.0;67.6] years old, 13 (41%) women) were included. Static PET parameters peak tumor-to-background ratio and metabolic tumor volume (respective thresholds of 1.9 and 1.5 mL) showed the best 84% accuracies for predicting PFS at 6 months (p = 0.02). These static PET parameters were also independent predictor of PFS in multivariate analysis (p ≤ 0.05).
Conclusion: In HGG patients having undergone a Stupp protocol, the absence of significant PET uptake after TMZ constitutes a favorable prognostic factor.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: